IL SOLFATO DI RAME - search results

Thụy Sĩ - Tiếng Đức - Swissmedic (Swiss Agency for Therapeutic Products)

tremfya 100 mg/1 ml injektionslösung im fertigpen

janssen-cilag ag - guselkumabum - injektionslösung im fertigpen - guselkumabum 100 mg, saccharum, histidinum, histidini hydrochloridum monohydricum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - plaque psoriasis, psoriasis-arthritis - biotechnologika

Liên Minh Châu Âu - Tiếng Đức - EMA (European Medicines Agency)

enspryng

roche registration gmbh - satralizumab - neuromyelitis optica - immunsuppressiva - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.

Liên Minh Châu Âu - Tiếng Đức - EMA (European Medicines Agency)

adtralza

leo pharma a/s - tralokinumab - dermatitis, atopisch - andere dermatologische präparate - adtralza is indicated for the treatment of moderate to severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.

Thụy Sĩ - Tiếng Đức - Swissmedic (Swiss Agency for Therapeutic Products)

skyrizi 150 mg lnjektionslösung in einer fertigspritze

abbvie ag - risankizumabum - lnjektionslösung in einer fertigspritze - risankizumabum 150 mg, natrii acetas trihydricus corresp. natrium 0.209 mg, acidum aceticum glaciale, trehalosum dihydricum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - plaque-psoriasis bei erwachsenen, psoriasis-arthritis - biotechnologika

Liên Minh Châu Âu - Tiếng Đức - EMA (European Medicines Agency)

bimzelx

ucb pharma s.a. - bimekizumab - psoriasis - immunsuppressiva - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.